NFKBIE
Overview
NFKBIE encodes IkB-epsilon, an inhibitor of NF-kB signaling. In the corpus it appears as a recurrent low-frequency driver in CLL and as an NF-kB pathway driver in classic Hodgkin lymphoma.
Alterations observed in the corpus
- Known lower-frequency CLL driver, reconfirmed as prognostic in U-CLL in the 1,148-patient CLL map PMID:35927489.
- Mutated in 15% of classic Hodgkin lymphoma cases profiled by WGS/WES (n=61); NF-kB pathway driver PMID:36723991.
- Novel recurrent promoter hotspot mutations in 14.5% of desmoplastic melanoma samples (9 at primary site, 2 at nearby secondary site); plus focal amplification in 2 tumors; biallelic selection demonstrated; loss of NFκB nuclear translocation in mutant cell lines, suggesting gain-of-function event suppressing NFκB signaling. PMID:26343386
Cancer types (linked)
- Chronic lymphocytic leukemia (CLLSLL) — prognostic in U-CLL PMID:35927489.
- Classic Hodgkin lymphoma (CHL) — 15% mutation frequency PMID:36723991.
Co-occurrence and mutual exclusivity
- Part of the NF-kB pathway driver set in cHL alongside TNFAIP3 PMID:36723991.
Therapeutic relevance
- No direct therapeutic link reported in the corpus.
Open questions
- Mechanistic role relative to other NF-kB drivers across B-cell malignancies remains open.
Sources
This page was processed by crosslinker on 2026-04-08. - PMID:26343386
This page was processed by wiki-cli on 2026-05-14.